Sirenia Capital Management LP Reports New 6.1% Stake in Immunome, Inc.

On May 15, 2026, Sirenia Capital Management LP and Alex Silverstein filed a Schedule 13G with the SEC, disclosing a new 6.1% stake in Immunome, Inc. (IMNM). The filing reveals that the reporting persons beneficially own 6,895,000 shares of common stock as of the event date on March 31, 2026. This position is held through an investment fund and a managed account, with Sirenia Capital Management LP serving as the investment adviser. Alex Silverstein, as the managing member of the general partner of Sirenia, shares voting and dispositive power over these securities. The reporting persons have certified that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This filing represents a significant increase in holdings from a previously unreported position, crossing the 5% ownership threshold that requires public disclosure under SEC regulations. The percentage calculation is based on 113,133,199 shares outstanding as of late February 2026.